INFORM | THIRD QUARTER OF 2021

Pandemic continues to impact business development Also in the third quarter of financial year 2021, HARTMANN’s business development remained closely linked to the course of the coronavirus pandemic. Across all business segments, the company generated sales revenues of EUR 1,704.9 million in the first nine months of 2021. This represents a moderate organic sales decline of -5.6% compared to the same period of the previ - ous year. This means that sales have been declining for three quarters in a row. Although numerous countries in Europe and elsewhere are grad- ually rolling back their coronavirus restrictions, the development of sales shows that the negative effects of the pandemic are persisting. At the same time, overall positive extraordinary effects of the pandemic have failed to materialize despite the increasing normalization of everyday life, e.g. which has resulted in a higher frequency of visits to doctors and pharmacies, as well as a slightly improved occupancy rate in hospitals and care facilities. In the Wound Management segment, sales in the first nine months of 2021 were only at the pre-pandemic level. In the Incontinence Management segment, sales did not reach pre-pandemic levels. In the Infection Management segment, reorders for disinfection products continued to decline due to the fact that customers are still holding large inventories of such products. Positive contribu - tions in previous quarters, mainly from examination gloves, failed to materialize between July and September. Ongoing negative effects of the coronavirus pandemic include a significant increase in freight costs and material prices. Similarly, budgetary and cost pressure in the healthcare systems intensi- fied. These market developments had a negative impact on the majority of our business segments. Recovery continues in Wound Management In the Wound Management segment, HARTMANN generated sales revenues of EUR 366.0 million in the first nine months of the year. Surgeries and the frequency of visits to doctors and pharmacies increased, so that the recovery of the Wound Man- agement business continued. Compared to the same period of the previous year, organic sales development in the Wound Man- agement segment was up by 10.1%. This means that sales in the first nine months of 2021 are only at the pre-pandemic level. Positive highlights in Q3 included antimicrobial and superab - sorbent wound dressings from the advanced wound care range. Business with traditional wound dressings and Vivano ® negative pressure wound therapy also made a positive contribution. Sales in the Incontinence Management segment amounted to EUR 505.3 million in the first nine months. This corresponds to an organic decline in sales of -2.5% compared to the same period of the previous year, and means that the pre-pandemic level of BUSINESS DEVELOPMENT IN THE FIRST THREE QUARTERS OF 2021 sales has not yet been reached. Although bed occupancy rates in medical facilities are on the rise, the increase is moderate. Despite a slight improvement, demand for care products in med- ical facilities, such as hospitals and retirement homes, remains low overall. Business has increased with solutions for the out-­ patient care of incontinent, active individuals. This includes pants, an incontinence product that is worn like underwear. Bed mats, skin care products and the MoliCare ® Premium Elastic inconti - nence slips also made a positive contribution. The Infection Management segment recorded sales of EUR 514.9 million in the reporting period. This corresponds to a strong organic decline in sales of -19.6% as compared to the same period of the previous year. Reorders for disinfection prod- ucts are currently at a low level due to the fact that customers are still holding large inventories of such products. This situation is currently leading to a massive drop in profitability. Neverthe- less, the market for disinfection products is growing compared to pre-pandemic levels as HARTMANN has been able to gain market share despite the current challenges. Demand for per- sonal protective equipment also weakened. In the third quarter of 2021, sales of examination gloves declined. The Other Group Activities segment generated sales of EUR 318.8 million. This corresponds to an organic increase in sales of 0.6% compared to the previous year. These sales figures include ex- change rate effects of -0.6% and in the main the divestment of Sanimed with a decline of -4.9%. At CMC Consumer Medical Care, reduced demand for cosmetic products led to declining sales. KNEIPP continues to successfully serve the trend towards greater health awareness and wellness at home. At KOB, the renewed increase in the number of sporting events led to higher demand for products for sports-related injuries, such as bandages. Total sales by business segment in EUR million and percent 366.0 | 21.5% 318.8 | 18.7% 505.3 | 29.6% 514.9 | 30.2% Wound Management Other Group Activities Incontinence Management Infection Management 4 Inform third quarter 2021 | Business development